Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | STAT5A | P42229 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 3/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229907 | 0.83 | PTGDR2 (0.37) | JAK3PTGDR2 | |
| SCHEMBL18202270 | 0.76 | HTR2A (0.40) | RPS6KA5 | |
| SCHEMBL18229866 | 0.76 | PTGDR2 (0.34) | PRKCBPTGDR2 | |
| SCHEMBL18202323 | 0.75 | HTR2A (0.39) | RPS6KA5 | |
| SCHEMBL29571670 | 0.75 | HTR2A (0.39) | RPS6KA5 | |
| SCHEMBL18239596 | 0.75 | RPS6KA5 (0.33) | JAK3RPS6KA5 | |
| SCHEMBL18202194 | 0.73 | EGFR (0.42) | RPS6KA5 | |
| SCHEMBL18202201 | 0.71 | CSNK1D (0.32) | RPS6KA5 | |
| SCHEMBL18202203 | 0.69 | PABPC1 (0.37) | — | |
| SCHEMBL18239659 | 0.69 | HTR2A (0.44) | JAK3STAT5AZAP70SYKPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | JAK3 331/4885STAT5A 580/4885ZAP70 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.